Allergan’s Acular
Executive Summary
Ophthalmic form of the NSAID (ketorolac) approved for relief of ocular itching caused by seasonal allergic conjunctivitis. Acular will be manufactured and marketed by Allergan, which has world marketing rights except in Japan; Syntex will provide the active ingredient. Acular will be available in the U.S. "by early spring" in 10 ml dropper bottles with 5 ml of solution. Syntex sales of oral and intramuscular ketorolac (Toradol) for pain management totaled $149 mil. in the U.S. and $197.8 mil. worldwide in FY 1992 (ended July 31), the company said in its annual report. Additional formulations of ketorolac under development include a topical gel, a transdermal patch and a sustained-release twice-daily tablet.